{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:31:51Z","timestamp":1791325911023,"version":"4.3.1"},"reference-count":56,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVES<\/jats:title>\n                    <jats:p>Evidence on the perinatal health of mother-infant dyads affected by opioids is limited. Elevated risks of opioid-related harms for people with opioid use disorder (OUD) increase the urgency to identify protective factors for mothers and infants. Our objectives were to determine perinatal outcomes after an OUD diagnosis and associations between opioid agonist treatment and birth outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We conducted a population-based retrospective study among all women with diagnosed OUD before delivery and within the puerperium period in British Columbia, Canada, between 2000 and 2019 from provincial health administrative data. Controlling for demographic and clinical characteristics, we determined associations of opioid agonist treatment on birth weight, gestational age, infant disorders related to gestational age and birth weight, and neonatal abstinence syndrome via logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The population included 4574 women and 6720 live births. Incidence of perinatal OUD increased from 166 in 2000 to 513 in 2019. Compared with discontinuing opioid agonist treatment during pregnancy, continuous opioid agonist treatment reduced odds of preterm birth (adjusted odds ratio: 0.6; 95% confidence interval: 0.4\u20130.8) and low birth weight (adjusted odds ratio: 0.4; 95% confidence interval: 0.2\u20130.7). Treatment with buprenorphine-naloxone (compared with methadone) reduced odds of each outcome including neonatal abstinence syndrome (adjusted odds ratio: 0.6; 95% confidence interval: 0.4\u20130.9).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Perinatal OUD in British Columbia tripled in incidence over a 20-year period. Sustained opioid agonist treatment during pregnancy reduced the risk of adverse birth outcomes, highlighting the need for expanded services, including opioid agonist treatment to support mothers and infants.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1542\/peds.2021-050279","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T04:32:08Z","timestamp":1630643528000},"source":"Crossref","is-referenced-by-count":42,"title":["Opioid Use Disorder and Perinatal Outcomes"],"prefix":"10.1542","volume":"148","author":[{"given":"Micah","family":"Piske","sequence":"first","affiliation":[{"name":"Centre for Health Evaluation and Outcome Sciences, St Paul\u2019s Hospital, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahmida","family":"Homayra","sequence":"additional","affiliation":[{"name":"Centre for Health Evaluation and Outcome Sciences, St Paul\u2019s Hospital, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong E.","family":"Min","sequence":"additional","affiliation":[{"name":"Centre for Health Evaluation and Outcome Sciences, St Paul\u2019s Hospital, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Centre for Health Evaluation and Outcome Sciences, St Paul\u2019s Hospital, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Marchand","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"},{"name":"Department of Family Practice, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Mead","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"},{"name":"Department of Family Practice, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Ng","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"},{"name":"Department of Family Practice, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Woolner","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"},{"name":"Department of Family Practice, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohdan","family":"Nosyk","sequence":"additional","affiliation":[{"name":"Centre for Health Evaluation and Outcome Sciences, St Paul\u2019s Hospital, Vancouver, British Columbia, Canada"},{"name":"Simon Fraser University, Faculty of Health Sciences, Burnaby, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"issue":"1","key":"2022010419404874000_B1","doi-asserted-by":"crossref","first-page":"E55","DOI":"10.9778\/cmajo.20140065","article-title":"Neonatal opioid withdrawal and antenatal opioid prescribing","volume":"3","author":"Turner","year":"2015","journal-title":"CMAJ Open"},{"key":"2022010419404874000_B2","volume-title":"Women\u2019s Health Surveillance Report","author":"Canadian Institute for Health Information","year":"2003"},{"key":"2022010419404874000_B3","volume-title":"Results from the 2007 National Survey on Drug Use and Health: National Findings","author":"Substance Abuse and Mental Health Services Administration","year":"2008"},{"issue":"2","key":"2022010419404874000_B4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2020.24991","article-title":"Neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010-2017","volume":"325","author":"Hirai","year":"2021","journal-title":"JAMA"},{"key":"2022010419404874000_B5","volume-title":"Effects of Opioid Agonist Treatment for Pregnant Opioid Dependent Women","author":"Berg","year":"2008"},{"key":"2022010419404874000_B6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ntt.2013.05.003","article-title":"The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations","volume":"39","author":"Jones","year":"2013","journal-title":"Neurotoxicol Teratol"},{"issue":"1","key":"2022010419404874000_B7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/AOG.0000000000002054","article-title":"Opioid use in pregnancy, neonatal abstinence syndrome, and childhood outcomes: executive summary of a joint workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation","volume":"130","author":"Reddy","year":"2017","journal-title":"Obstet Gynecol"},{"key":"2022010419404874000_B8","first-page":"CD006318","article-title":"Maintenance agonist treatments for opiate-dependent pregnant women","volume":"11","author":"Minozzi","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2022010419404874000_B9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/ADM.0000000000000308","article-title":"Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance","volume":"11","author":"Klaman","year":"2017","journal-title":"J Addict Med"},{"issue":"12","key":"2022010419404874000_B10","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1111\/add.13462","article-title":"Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child","volume":"111","author":"Zedler","year":"2016","journal-title":"Addiction"},{"issue":"3","key":"2022010419404874000_B11","doi-asserted-by":"crossref","first-page":"e20183801","DOI":"10.1542\/peds.2018-3801","article-title":"Public health surveillance of prenatal opioid exposure in mothers and infants","volume":"143","author":"Honein","year":"2019","journal-title":"Pediatrics"},{"issue":"8","key":"2022010419404874000_B12","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1542\/hpeds.2018-0227","article-title":"Increased severity of neonatal abstinence syndrome associated with concomitant antenatal opioid and benzodiazepine exposure","volume":"9","author":"Sanlorenzo","year":"2019","journal-title":"Hosp Pediatr"},{"issue":"3","key":"2022010419404874000_B13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.drugalcdep.2004.03.012","article-title":"Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure","volume":"75","author":"Choo","year":"2004","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"2022010419404874000_B14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jogc.2016.11.009","article-title":"Infants born to opioid-dependent women in Ontario, 2002-2014","volume":"39","author":"Brogly","year":"2017","journal-title":"J Obstet Gynaecol Can"},{"issue":"24","key":"2022010419404874000_B15","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"2022010419404874000_B16","unstructured":"British Columbia Ministry of Health\n          . PharmaNet. Available at: www.health.gov.bc.ca\/data\/. Accessed September 19, 2020"},{"key":"2022010419404874000_B17","unstructured":"British Columbia Ministry of Health\n          . Discharge Abstract Database (Hospital Separations). Available at: www.health.gov.bc.ca\/data\/. Accessed September 19, 2020"},{"key":"2022010419404874000_B18","unstructured":"British Columbia Ministry of Health\n          . Medical Services Plan (MSP) Payment Information File. Available at: www.health.gov.bc.ca\/data\/. Accessed September 19, 2020"},{"key":"2022010419404874000_B19","unstructured":"British Columbia Ministry of Health National Ambulatory Care Reporting System (NACRS)\n          . Available at: www.health.gov.bc.ca\/data\/. Accessed September 19, 2020"},{"key":"2022010419404874000_B20","unstructured":"British Columbia Vital Statistics Agency\n          . Vital Statistics Deaths. Available at: www.health.gov.bc.ca\/data\/. Accessed September 19, 2020"},{"key":"2022010419404874000_B21","unstructured":"Perinatal Services British Columbia\n          . British Columbia Perinatal Data Registry. Available at: www.health.gov.bc.ca\/data\/. Accessed September 19, 2020"},{"key":"2022010419404874000_B22","unstructured":"Ministry of Public Safety and Solicitor General\n          . BC Corrections Dataset. Available at: www.health.gov.bc.ca\/data\/. Accessed September 19, 2020"},{"issue":"9","key":"2022010419404874000_B23","doi-asserted-by":"crossref","first-page":"e036102","DOI":"10.1136\/bmjopen-2019-036102","article-title":"Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada","volume":"10","author":"Piske","year":"2020","journal-title":"BMJ Open"},{"issue":"8","key":"2022010419404874000_B24","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/add.14947","article-title":"The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada","volume":"115","author":"Piske","year":"2020","journal-title":"Addiction"},{"key":"2022010419404874000_B25","doi-asserted-by":"crossref","first-page":"m772","DOI":"10.1136\/bmj.m772","article-title":"Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study","volume":"368","author":"Pearce","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"2022010419404874000_B26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/EDE.0000000000000780","article-title":"Methadone versus buprenorphine for opioid use dependence and risk of neonatal abstinence syndrome","volume":"29","author":"Lemon","year":"2018","journal-title":"Epidemiology"},{"key":"2022010419404874000_B27","unstructured":"Government of British Columbia\n          . Product Identification Numbers (PINs). Available at: https:\/\/www2.gov.bc.ca\/gov\/content\/health\/practitioner- professional-resources\/pharmacare\/pharmacies\/product-identification- numbers. Accessed August 19, 2020"},{"key":"2022010419404874000_B28","doi-asserted-by":"crossref","first-page":"j3326","DOI":"10.1136\/bmj.j3326","article-title":"Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study","volume":"358","author":"Huybrechts","year":"2017","journal-title":"BMJ"},{"issue":"19","key":"2022010419404874000_B29","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":"Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study","volume":"264","author":"Regier","year":"1990","journal-title":"JAMA"},{"key":"2022010419404874000_B30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.drugalcdep.2018.08.013","article-title":"Multicomorbidity of chronic diseases and substance use disorders and their association with hospitalization: Results from electronic health records data","volume":"192","author":"Wu","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"2022010419404874000_B31","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/00005650-199508000-00004","article-title":"A chronic disease score with empirically derived weights","volume":"33","author":"Clark","year":"1995","journal-title":"Med Care"},{"key":"2022010419404874000_B32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2431-12-9","article-title":"The test characteristics of head circumference measurements for pathology associated with head enlargement: a retrospective cohort study","volume":"12","author":"Daymont","year":"2012","journal-title":"BMC Pediatr"},{"key":"2022010419404874000_B33","volume-title":"A Health Professional\u2019s Guide for Using the Growth Chart for Canada","author":"British Columbia Children's Hospital","year":"2014"},{"issue":"11","key":"2022010419404874000_B34","first-page":"927","article-title":"Population-based microcephaly surveillance in the United States, 2008-2013: an analysis of potential sources of variation","volume":"106","author":"Janet","year":"2016","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"4","key":"2022010419404874000_B35","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1097\/AOG.0000000000001108","article-title":"Committee opinion No. 644: The Apgar score","volume":"126","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"6","key":"2022010419404874000_B36","doi-asserted-by":"crossref","first-page":"e196405","DOI":"10.1001\/jamanetworkopen.2019.6405","article-title":"Prenatal risk factors and perinatal and postnatal outcomes associated with maternal opioid exposure in an urban, low-income, multiethnic us population","volume":"2","author":"Azuine","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2022010419404874000_B37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/ppe.12443","article-title":"The role of preterm birth in the association between opioid maintenance therapy and neonatal abstinence syndrome","volume":"32","author":"Lemon","year":"2018","journal-title":"Paediatr Perinat Epidemiol"},{"key":"2022010419404874000_B38","unstructured":"Canadian Institute for Health Information\n          . ICD-10-CA and CCI evolution tables. Available at: https:\/\/secure.cihi.ca\/estore\/productSeries.htm?pc=PCC217. Accessed August 19, 2020"},{"key":"2022010419404874000_B39","volume-title":"British Columbia Centre on Substance Use","author":"Guidance for Injectable Opioid Agonist Treatment for Opioid Use Disorder","year":"2017"},{"key":"2022010419404874000_B40","volume-title":"A Guideline for the Clinical Management of Opioid Use Disorder: British Columbia Centre on Substance Use","year":"2017"},{"key":"2022010419404874000_B41","unstructured":"BC Centre on Substance Use (BCCSU)\n          . Treatment of opioid use disorder during pregnancy: Guideline supplement. 2018. Available at: www.perinatalservicesbc.ca\/Documents\/Guidelines-Standards\/Maternal\/OUD- Pregnancy.pdf. Accessed August 19, 2020"},{"key":"2022010419404874000_B42","volume-title":"Generalized, Linear, And Mixed Models","author":"McCulloch","year":"2008","edition":"2nd ed."},{"issue":"2","key":"2022010419404874000_B43","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/ADM.0000000000000099","article-title":"The effect of methadone dose regimen on neonatal abstinence syndrome","volume":"9","author":"McCarthy","year":"2015","journal-title":"J Addict Med"},{"key":"2022010419404874000_B44","volume-title":"Clinical Guideline for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants","author":"Substance Abuse and Mental Health Services Administration","year":"2018"},{"issue":"4","key":"2022010419404874000_B45","doi-asserted-by":"crossref","first-page":"e191430","DOI":"10.1001\/jamanetworkopen.2019.1430","article-title":"Benzodiazepines and the Z-drugs in pregnancy-reasonably reassuring for neurodevelopment but should we really be using them?","volume":"2","author":"Vigod","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2022010419404874000_B46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/ADM.0000000000000183","article-title":"Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study: re: meyer et\u00a0al","volume":"10","author":"McCarthy","year":"2016","journal-title":"J Addict Med"},{"issue":"2","key":"2022010419404874000_B47","article-title":"Pregnant women and substance use: fear, stigma, and barriers to care","volume":"3","author":"Stone","year":"2015","journal-title":"Health Justice"},{"key":"2022010419404874000_B48","volume-title":"A Guideline for the Clinical Management of Opioid Use Disorder","author":"British Columbia Centre on Substance Use","year":"2017"},{"issue":"3","key":"2022010419404874000_B49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/00952990.2019.1694536","article-title":"A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States","volume":"46","author":"Lister","year":"2020","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"7","key":"2022010419404874000_B50","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0706743717711167","article-title":"The state of opioid agonist therapy in Canada 20 years after federal oversight","volume":"62","author":"Eibl","year":"2017","journal-title":"Can J Psychiatry"},{"issue":"5","key":"2022010419404874000_B51","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1701-2163(16)35245-8","article-title":"A rooming-in program to mitigate the need to treat for opiate withdrawal in the newborn","volume":"34","author":"Hodgson","year":"2012","journal-title":"J Obstet Gynaecol Can"},{"issue":"6","key":"2022010419404874000_B52","doi-asserted-by":"crossref","first-page":"e20152929","DOI":"10.1542\/peds.2015-2929","article-title":"Rooming-in to treat neonatal abstinence syndrome: improved family-centered care at lower cost","volume":"137","author":"Holmes","year":"2016","journal-title":"Pediatrics"},{"issue":"5","key":"2022010419404874000_B53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1055\/s-0035-1566295","article-title":"Rooming-in for infants at risk of neonatal abstinence syndrome","volume":"33","author":"McKnight","year":"2016","journal-title":"Am J Perinatol"},{"issue":"2","key":"2022010419404874000_B54","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1055\/s-0035-1556740","article-title":"Prescription opioids in pregnancy and birth outcomes: a review of the literature","volume":"4","author":"Yazdy","year":"2015","journal-title":"J Pediatr Genet"},{"key":"2022010419404874000_B55","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drugalcdep.2016.09.021","article-title":"The relationships of childhood trauma and adulthood prescription pain reliever misuse and injection drug use","volume":"169","author":"Quinn","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"2022010419404874000_B56","doi-asserted-by":"crossref","first-page":"1754195","DOI":"10.1155\/2016\/1754195","article-title":"Misuse of prescription opioid medication among women: a scoping review","volume":"2016","author":"Hemsing","year":"2016","journal-title":"Pain Res Manag"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2021-050279\/1228262\/peds_2021050279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2021-050279\/1228262\/peds_2021050279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T14:41:28Z","timestamp":1641307288000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/148\/4\/e2021050279\/181304\/Opioid-Use-Disorder-and-Perinatal-Outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":56,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,10,1]]},"published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2021-050279","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]},"article-number":"e2021050279"}}